BridgeMD
New treatment option for Maculopathy
Official title AVIGA3 (Cohort 2.0)
ClinicalTrials.gov ID: NCT07255859
What this study is testing
- What it's testing
- Age-Macular Degeneration (AMD) is a common eye condition and a leading cause of vision loss among people age 50 and older. It causes damage to the macula, a small area near the centre of the retina needed for sharp, central vision.
- Which group you join is decided by chance.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 50 to 99
You may be able to join if
- people in the age group ≥ 50 to 99 years old.
- Both genders
- Able to understand verbal spoken instructions in British/American English, Chinese or Bahasa Melayu and demonstrate device functionality and...
- Able to turn on and connect the web-camera to a computer independently or with the help of family.
- people undergoing treatment for Wet-AMD without any signs and symptoms of recurrence of active AMD (AMD recurrence: choroidal neovascularisation...
You likely can't join if
- Unable to understand verbal spoken instructions and demonstrate device functionality and implementation.
- Unable to turn on and connect the web-camera to a computer independently.
- Any ocular surgery in the previous 3 months, or vitrectomy in the previous 12 months
- Any history of macular pathology unrelated to AMD affecting vision or contributing to the presence of intraretinal or subretinal fluid in the study...
- Any concurrent intraocular condition in the study eye that, in the opinion of the investigator, could either reduce the potential for visual...
- Any prior or concomitant treatment for CNV or vitreomacular-interface abnormalities in the study eye.
See the full eligibility criteria
- people in the age group ≥ 50 to 99 years old.
- Both genders
- Able to understand verbal spoken instructions in British/American English, Chinese or Bahasa Melayu and demonstrate device functionality and implementation.
- Able to turn on and connect the web-camera to a computer independently or with the help of family.
- people undergoing treatment for Wet-AMD without any signs and symptoms of recurrence of active AMD (AMD recurrence: choroidal neovascularisation, intraretinal or subretinal fluid is present) with OCT lesion fluid volume...
- Ability to comply with the study protocol, in the investigator's judgment.
- people must be able to understand and provide informed consent. A signed informed consent form must be provided before any study assessments.
- Unable to understand verbal spoken instructions and demonstrate device functionality and implementation.
- Unable to turn on and connect the web-camera to a computer independently.
- Any ocular surgery in the previous 3 months, or vitrectomy in the previous 12 months
- Any history of macular pathology unrelated to AMD affecting vision or contributing to the presence of intraretinal or subretinal fluid in the study eye
- Any concurrent intraocular condition in the study eye that, in the opinion of the investigator, could either reduce the potential for visual improvement or require medical or surgical intervention during the study
- Any prior or concomitant treatment for CNV or vitreomacular-interface abnormalities in the study eye.
- History of idiopathic or autoimmune-associated uveitis in either eye
- Active ocular inflammation or suspected or active ocular or periocular infection in either eye.
The study team makes the final eligibility decision.
Where it's taking place
- Singapore, Singapore
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 50 years to 99 years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Singapore, Singapore. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.